Hence, in order to select appropriate target proteins that directly influence known cancer pathways, the current analysis builds—first and foremost—on the preclinical data published by Souza et al., who demonstrated that hsa-miR-375 has a functional binding site on the mRNA of the dexamethasone-induced ras-related protein (RASD1) [12]. Here, RASD1 is linked to cancer.